Study Overview:
This study looks at how well a medicine called donanemab helps people with early memory and thinking problems. The study will last for about one and a half years. The main goal is to see if the medicine can slow down problems with thinking and daily activities. Eligibility:
To join, participants should have had memory problems for at least six months and show signs of a condition called dementia with Lewy bodies. They need to have a score of 20 or higher on a test called the Montreal Cognitive Assessment (MoCA). Participants also need to have certain results from blood and spinal fluid tests. They should have someone they know well to help with the study. Key Points:
This study looks at how well a medicine called donanemab helps people with early memory and thinking problems. The study will last for about one and a half years. The main goal is to see if the medicine can slow down problems with thinking and daily activities. Eligibility:
To join, participants should have had memory problems for at least six months and show signs of a condition called dementia with Lewy bodies. They need to have a score of 20 or higher on a test called the Montreal Cognitive Assessment (MoCA). Participants also need to have certain results from blood and spinal fluid tests. They should have someone they know well to help with the study. Key Points:
- The study will last for 1.5 years.
- Participants need to have a reliable study partner.
- Certain medical conditions or history may prevent participation.
How understandable was the trial content above?
Hard to understand
Easy to understand